Showing posts with label Bristol-Myers Squibb. Show all posts
Showing posts with label Bristol-Myers Squibb. Show all posts

Friday, March 25, 2011

FDA approves Yervoy (ipilimumab) to treat melanoma

FDA approves new treatment for a type of late-stage skin cancer
Melanoma patients lived longer with treatment

The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.

Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.

“Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient’s life,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA’s Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."

Monday, June 7, 2010

Optimal treatment for CML (Chronic Myeloid Leukemia)

What's the optimal treatment for CML (Chronic Myeloid Leukemia)?  In the New England Journal of Medicine (NEJM), there were a few interesting articles this week that caught my attention:
  • Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Both of these studies were comparing imatinib (Gleevec) to newer drugs (dasatinib or Sprycel and nilotinib or Tasigna). In both cases, the newer agent appeared to result in better clinical responses (see conclusions below). If this is now the case, where does imatinib fall into treatment regimens for CML?  Who's going to want to receive Gleevec for their CML?

Conclusions: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML.

Conclusions: Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome–positive CML.

Friday, July 31, 2009

FDA approves Onglyza (saxagliptin)


FDA approved Onglyza (saxagliptin) for type 2 diabetes. This is the 2nd DPP-IV inhibitor to be approved. The first DPP-IV was Januvia (sitagliptin).

Here's the FDA press release:
The U.S. Food and Drug Administration today approved Onglyza (saxagliptin), a once-daily tablet to treat Type 2 diabetes in adults. The medication is intended to be used with diet and exercise to control high blood sugar levels.

The hormone insulin keeps blood sugar (glucose) levels within a narrow range in people who don’t have diabetes. People with Type 2 diabetes are either resistant to insulin or do not produce enough insulin to maintain normal blood sugar levels.

Onglyza is in a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors which stimulate the pancreas to make more insulin after eating a meal.

“Keeping blood sugar levels in adequate control is essential to the good health of the 24 million people in the United States with Type 2 diabetes,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “High blood sugar levels can cause blurry vision and excessive urination and eventually result in such serious conditions as kidney and eye disease.”

The most common side effects observed with Onglyza are upper respiratory tract infection, urinary tract infection, and headache. Other side effects include allergic-like reactions such as rash and hives.

Approval of Onglyza was primarily based on the results of eight clinical trials. The application seeking FDA approval was submitted before December 2008 when the agency recommended that manufacturers of new diabetes drugs carefully design and evaluate their clinical trials for cardiovascular safety. Although Onglyza was not associated with an increased risk for cardiovascular events in patients who were mainly at low risk for these events, the FDA is requiring a postmarket study that will specifically evaluate cardiovascular safety in a higher risk population.

Onglyza is manufactured by Bristol-Myers Squibb Co. of Princeton, N.J., and marketed by Bristol-Myers and AstraZeneca Pharmaceuticals LP, of Wilmington, Del.

Friday, July 10, 2009

FDA finally approves Effient (prasugrel)


The FDA has finally approved Effient (prasugrel), a thienopyridine that is similar to Plavix (clopidogrel). In fact, prasugrel has been compared to clopidogrel. The TRITON-TIMI 38 study (comparing prasugrel against clopidogrel) was published in the New England Journal of Medicine (NEJM) back in November 2007! That's not a typo. 2007. The FDA wanted more safety data (which is why they launched the TRILOGY ACS study). I guess the FDA got what they needed. Here are the details straight from the FDA (with a few of my comments):

FDA Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients
The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery. (it's about time, isn't it? The TRITON-TIMI 38 study came out in November, 2007! OK, you wanted more safety data because of bleeding. Fine.)

During an angioplasty, a balloon is used to open the artery that has been narrowed by atherosclerotic plaque. Often, a tiny wire mesh scaffold (stent) is inserted into the blood vessel to help keep the artery open after the procedure. Platelets in the blood can clump around the procedure site, causing clots that can lead to heart attack, stroke, and death.

Effient (prasugrel) was studied in a 13,608-patient trial (this is the TRITON-TIMI 38 study) comparing it to the blood-thinning drug, Plavix (clopidogrel), in patients with a threatened heart attack or an actual heart attack who were about to undergo angioplasty.

The fraction of patients who had subsequent non-fatal heart attacks was reduced from 9.1 percent in patients who received Plavix to 7.0 percent in patients who received Effient.While the numbers of deaths and strokes were similar with both drugs, patients with a history of stroke were more likely to have another stroke while taking Effient. In addition, there was a greater risk of significant, sometimes fatal bleeding seen in patients who took Effient. (So, Effient may be more effective than Plavix in certain patients, but it also appears to have a higher risk for bleeding)

“Effient offers physicians an alternative treatment for preventing dangerous blood clots from forming and causing a heart attack or stroke during or after an angioplasty procedure,” said John Jenkins, M.D., director of the Office of New Drugs, in the FDA’s Center for Drug Evaluation and Research.“Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug.” (in other words, doctors now have to choose between Plavix vs. Effient. How are they to make this decision? Bleeding risk? Anti-platelet resistance?)

The drug’s labeling will include a boxed warning alerting physicians that the drug can cause significant, sometimes fatal, bleeding. The drug should not be used in patients with active pathological bleeding, a history of mini-strokes (transient ischemic attacks) or stroke, or urgent need for surgery, including coronary artery bypass graft surgery. (we all know that blood thinners can cause serious bleeding, so this is plain common sense)
So, Effient is an alternative to Plavix. Now, the big question now is: who should get Effient and who should get Plavix? If you need a thienopyridine, which would you prefer? I'm not going to get started about anti-platelet resistance on this blog post.
  • Effient is manufactured by Eli Lilly and Company of Indianapolis, in partnership with Tokyo-based Daiichi Sankyo Ltd.
  • Plavix is marketed by a sanofi-aventis U.S. LLC, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
There are many other acute coronary syndrome (ACS) drugs on the horizon, including thrombin receptor antagonists (TRAs) like SCH 530348 and novel anti-platelet drugs like cangrelor and AZD6104. I wonder if (or when) we'll see these new agents get approved.

Wednesday, July 8, 2009

Elotuzumab: Anti-CS1 Antibody for Multiple Myeloma


Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody and is currently being studied for the treatment of multiple myeloma. Which do you think is easier to say: Elotuzumab or HuLuc63? Why do cancer therapies need to have such complicated names?

According to PDL BioPharma:
HuLuc63 is a novel humanized antibody that binds to CS1, a cell surface glycoprotein that is highly expressed on myeloma cells but minimally expressed on normal cells. HuLuc63 may induce anti-tumor effects through antibody-dependent cellular cytotoxicity activity on myeloma cells. Recent preclinical data highlight in vitro and in vivo studies of HuLuc63 and support advancement into the clinic. Developed by PDL BioPharma researchers, HuLuc63 is presently under phase I clinical investigation in relapsed multiple myeloma to evaluate the safety of this novel antibody in this important hematologic malignancy.
Last year, the Multiple Myeloma Research Consortium (MMRC) announced the initiation of a multi-center, open-label, dose-escalation Phase Ib study that includes a three-drug combination study of elotuzumab, plus REVLIMID (lenalidomide), plus dexamethasone for the treatment of multiple myeloma in patients who are experiencing a relapse. Emory University's Winship Cancer Institute, Washington University, and St. Vincent's Comprehensive Cancer Center of Saint Vincent Catholic Medical Centers of New York will evaluate the maximum tolerated dose of elotuzumab in combination with label dosing of lenalidomide and dexamethasone.

Targeted therapies are becoming the way of the future in the world of oncology. It's quite exciting to see how these agents act on specific molecular markers such as glycoprotein receptors. Medical students who have a strong interest in oncology should make sure they're really paying attention when they take their molecular biology courses (course 7.28 for you MIT undergraduate students).

Bristol-Myers Squibb (BMS) and PDL BioPharma announced an agreement for the global development and commercialization of elotuzumab (HuLuc63).

Wednesday, June 10, 2009

Will Roche have the first PPAR agonist?


The Wall Street Journal (WSJ): "Roche Diabetes Drug in Late-Stage Test"

Will Roche be the first with a dual PPAR agonists? Thiazolidinediones (TZDs) like Avandia (rosiglitazone) and Actos (pioglitazone) bind to peroxisome proliferator-activated receptors (PPARs). Several new thiazolidinediones are being investigated as "dual PPAR agonists." One such compound is aleglitazar (made by Roche). My gut tells me that they won't be marketed as TZDs. "Dual PPAR Agonist" sounds better, doesn't it?

A few years ago, AstraZeneca stopped R&D on a similar drug, Galida (tesaglitazar), while Bristol-Myers Squibb (BMS) stopped work on a drug called Pargluva (muraglitazar). TZDs just haven't had much luck, have they? Remember Rezulin (troglitazone)? It was the first TZD and it got pulled from the market because of liver problems.

Monday, February 23, 2009

The European Commission Approves Efient (prasugrel

No, not Effient (which is the proposed US tradename). Efient (prasugrel) has been approved in Europe for acute coronary syndrome (ACS) patients undergoing PCI. The annoucement was made by Daiichi SankyoCompany, Limited and Eli Lilly and Company.

Two of the major prasugrel studies are:
  • TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction), and
  • TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes),
Prasugrel is a dihydropyridine that is currently under FDA review. The other dihydropyridine you're probably familiar with is Plavix (clopidogrel) which is marketed by sanofi-aventis U.S. LLC and Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.